ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)
Celltrion USA has expanded access toZYMFENTRA®(infliximab-dyyb),the first and only FDA-approved subcutaneous (SC) infliximab,to a significant share of the U.S. market











